The development of cures, vaccines and better treatments for HIV/AIDS is an urgent global health priority. This team of seven groups in Sydney and Melbourne will study how HIV can lie dormant in some parts of the body, evading eradication by HIV therapy, as well as how the immune system responds to the virus. This will allow for design of novel vaccines and treatments. The researchers have skills in basic virology and immunology, and translating laboratory findings into human clinical trials.
Addressing The Major Challenges In HIV Vaccine And Cure Research
Funder
National Health and Medical Research Council
Funding Amount
$16,136,755.00
Summary
HIV remains one of the defining global health challenge of our times. 37 million people are living with HIV with 2 million new infections each year. Despite advances in management of HIV infection with antiretroviral therapy, there is still no cure, no effective vaccine, and several co-infections reduce life expectancy. This program assembles Australia’s leading HIV researchers to use innovative basic and translational science to tackle priority areas in controlling the HIV epidemic.
Risk Factors, Early Diagnosis, And Effective Interventions For Neurocognitive Disorders
Funder
National Health and Medical Research Council
Funding Amount
$7,013,299.00
Summary
This program will focus on early detection of dementia, identification of novel risk factors, and development of new treatments, to help the burden of dementia in our community. It will build on three longitudinal studies – Memory and Ageing Study, Older Australian Twins Study and Sydney Centenarian Study, and three international consortia – COSMIC, STROKOG and ICC-Dementia, that the investigators have developed to achieve these aims. A prevention trial for post-stroke dementia is planned
Using Healthcare Wisely: Reducing Inappropriate Use Of Tests And Treatments
Funder
National Health and Medical Research Council
Funding Amount
$9,578,895.00
Summary
Overdiagnosis and overtreatment as unintended consequences of modern healthcare due to expanded disease definitions labelling people with mild problems or at low risk of illness, diagnostic tests identifying inconsequential abnormalities and screening programs detecting disease that won’t progress. The result is much harm and unsustainable overuse. We will research the prevalence, causes and consequences of overdiagnosis and overtreatment, evaluate solutions and widely disseminate findings.
Social media, weather forecasting and mineral exploration are driven by Big Data enabled by new technologies. Likewise, disease prevention, diagnosis and prediction is moving towards personalised and precision medicine, facilitated by novel genomics technologies. This Program of research will develop analysis methods and tools and apply them to clinical genomics data in neurological and psychiatric disorders, thereby paving the way for the translation of genomic tools to common diseases.
Frontotemporal Dementia And Motor Neurodegenerative Syndromes
Funder
National Health and Medical Research Council
Funding Amount
$17,069,580.00
Summary
Frontotemporal degeneration of the brain is a leading cause of morbidity due to a pathologically heterogeneous, rapidly-progressive group of disorders with behavioural, language and motor deficits. Our internationally recognized team will continue to develop the necessary tools and therapies to effectively diagnose, manage and treat these disorders. Our focus in this program is to understand the unusual genetics underpinning these disorders, and to fast track any potential treatments.
Generating The Evidence To Control Cancer And Optimise Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$6,564,341.00
Summary
Our Program addresses the public health aspects of common cancers, particularly cancers of the skin and gynaecological tracts. Each year in Australia, nearly 400,000 people are treated for skin cancer, and more than 3,500 women develop ovarian or uterine cancer. Our aims are first, to understand how we might prevent these cancers in the future; second, to enhance diagnosis of these cancers; and third, to improve the survival and quality of life for people who are diagnosed with these cancers